Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Constitutive meeting of Biohit Oyj’s Board of Directors

Biohit

Biohit Oyj, Other information disclosed according to the rules of the Exchange, June 5, 2025 at 6:00 pm local time (EEST)

Biohit Oyj’s Board of Directors has in its meeting on June 5, 2025 elected LL.D, Lic (BA) Vesa Silaskivi as the Chairman of the Board of Directors.

Silaskivi is an experienced board professional and thus a valuable contributor to the company’s growth.

Additional information: 
CEO Jussi Hahtela, Biohit Oyj

tel. +358 9 773 861

investor.relations@biohit.fi
www.biohithealthcare.com

 

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group. www.biohithealthcare.com

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.